Lupin launches rheumatoid arthritis drug Leflunomide in US
Mumbai, Baltimore: Drugmaker Lupin Limited has announced the launch of Leflunomide Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.The product would be manufactured at Lupin's Pithampur (Unit I) facility in India. Leflunomide Tablets USP, 10 mg and 20 mg, is the generic equivalent of Arava® Tablets, 10 mg and...
Mumbai, Baltimore: Drugmaker Lupin Limited has announced the launch of Leflunomide Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.
Read also: Lupin gets USFDA nod to generic version of ProAir HFA
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd